Jo Churchill
Main Page: Jo Churchill (Conservative - Bury St Edmunds)(2 years, 1 month ago)
Public Bill CommitteesThank you. We will be finishing at 2.20 pm, so Members should keep their questions brief, and answers should be as precise and brief as possible.
Q
Penny Hawkins: Right, there were quite a few components to that question, so if I start to go off topic, do please bring me back. I will start by saying that my area of expertise is the Animals (Scientific Procedures) Act 1986, so while I am aware that there are various pieces of legislation and codes of practice that regulate how farmed animals are kept and what it is permissible to do to them—of course, the Animal Welfare Act 2006 comes into play if farm animals are cruelly treated—what I really know about is the 1986 Act.
That was a major concern for the RSPCA, because when you look at the draft Bill, there is actually no mention at all of the Animals (Scientific Procedures) Act, which I will call ASPA for short from now on. The drafting team kindly gave us some of their time, so I now understand that every new line—every new precision-bred line that is created and that will then go on to fall under this Bill—will still require licensing under the ASPA for the foreseeable future.
That is absolutely essential, because within the ASPA, you have a framework for minimising the harms to animals, for reducing or avoiding wastage, and for ensuring that gene edited animals are properly characterised or phenotyped, so you understand the physical impact on the animal. There are also proper requirements for welfare assessment and, very importantly, a harm-benefit analysis and ethical review of every line, as you mentioned. In cases of special ethical animal welfare or societal concern, there is the provision to ask the Animals in Science Committee to review the project licence application, which is also critical.
The key reason why the harm-benefit analysis is essential is that at the moment, as drafted—and as previous people who have appeared before the Committee have explained—there is nothing in there about permissible purposes, less permissible purposes or purposes that should be really carefully scrutinised. So I think the ASPA is and will remain an essential safeguard to ensure that there is proper risk minimisation for animals, ethical review, and an element of social licence to use these techniques. People have to remember that the public need to consent to this, and at the moment, there are deep-seated public concerns that have not been properly explored.
Q
Penny Hawkins: Indeed. I think some very useful lessons can be learnt from the way in which genetically altered laboratory animals are regulated, but I emphasise that, within a laboratory setting, genetically altered laboratory animals include those in which genes have been inserted from other species. We are very clear that within this Bill we are talking just about gene editing and not about deliberate transgenesis, although there have been some discussions about potential accidental additions of exogenous material.
When genetically altered animals are created under the ASPA, a licence is required for their creation, because, obviously, regulated scientific procedures are required in order to generate these animals—procedures that relate to, for example, administering substances to animals so that they produce large numbers of eggs, or super-ovulation, removing those eggs from animals, preparing other animals to receive the gene edited pregnancies, and so on. All those require licensing, and then, when the line of genetically altered animals has been created, they have to be, as I mentioned, phenotyped. That is a battery of behavioural and biochemical tests to look at what the eventual genetic alteration was and to look at the whole animal that this creates—the phenotype.
There is a system of licensing under which the impact on the animal is categorised as mild, moderate or severe. If a researcher or research team can demonstrate that the gene edit they have done is stable for at least two generations, and if they have phenotyping data and animal welfare assessment data to demonstrate that the animal is not going to suffer as a result of being gene edited—the impact would have to be what is referred to as below threshold; not even mild suffering—then, in those circumstances, they can apply for the breeding of that particular line to be released from the controls of ASPA. That would mean that those animals would still be bred in a laboratory under all the codes of practice that normally apply to laboratory animals, but a licence would not be required in order to breed the animals, because there is no risk to their welfare because of the gene edit.
Those are the safeguards in place for laboratory animals. The issue with farmed animals is that, obviously, if they are released from ASPA and their breeding is then controlled or regulated by this PB legislation, they will not be held in a laboratory setting, with all the controls that that entails; they will join the national herd or flock. That is a very different environment, and it can be far from clear how the genes will express themselves once they are in that environment.
Also, this Bill presumably applies to other animals: companion animals, wild animals and sporting animals. At the moment, for example, projects are under way to look at gene editing grey squirrels to result in fewer females being born or male infertility. Presumably, their breeding will also be covered by the Bill. And when they are released, they really will be released into the wild. Again, that is an extremely different environment. So the safeguards that laboratory animals have will be severely reduced or absent for other types of animal.
We have until 2.50 pm for this session, so please could you introduce yourselves very briefly and then we will move straight into questions?
Pat Thomas: Good afternoon, and thank you for having us here today. My name is Pat Thomas. I am the co-founder and co-director of Beyond GM. I come from a journalistic background. I am a former trustee of the Soil Association and the Organic Research Centre, and I currently sit on the board of the Nuffield Council on Bioethics’ dialogues on genetically engineered animals.
Lawrence Woodward: I am Lawrence Woodward. I am co-director of Beyond GM; I am also a director of Whole Health Agriculture. I am an adviser to the Seed Sovereignty UK and Ireland programme. My previous life was as director of the Organic Research Centre, during which time I was involved in setting up an organic seed breeding company, developing a programme of evolutionary plant breeding. I was also a founder and director of the European Consortium for Organic Plant Breeding.
Q
Lawrence Woodward: The first issue is clarity of definition and terminology, which indicates concerns and differences of view regarding areas of risk. We start with this terminology, “precision breeding”, which is found nowhere else in any regulation of any other authority—it does not exist. It is a new term, and the definition of what that is, the description of what that is, only exists in this Bill and nowhere else, so there is a question about where safety issues and issues of regulation and risk assessment come in.
The Bill itself starts off with the premise that all these technologies arise from genetically modified organisms. The definitions in the Bill start off with GMOs as defined in the Genetically Modified Organisms (Deliberate Release) Regulations 2002. Those definitions have given rise over the years to contested science in relation to risk assessment and safety. The Bill goes on to say that any of those techniques under those GMO regulations can be considered to be precision breeding if they could have been achieved by traditional processes, but there is no international clarity about what traditional breeding or traditional processes actually are. The narrative in the UK is, “This is traditional breeding”, but different people mean different things by that. In fact, I noted that several speakers on Tuesday talked about conventional breeding, which is probably more accurate. When we talk about that definition of traditional breeding or conventional breeding in modern times, the methods are very different, and the contention is that the damage within the breeding process—the potential risks within the genome—varies according to the different methods.
The evidence presented by the Advisory Committee on Releases to the Environment and numerous scientific bodies in this country is that risk can be assessed adequately on the basis of the final product, on the phenotype: what it looks like, and how equivalent it is to something that comes from conventional or traditional breeding. That, it has to be said, is the opinion of most research establishments and plant breeders in the UK and in some other countries, but it is not true to say that it is an overwhelming consensus. There is a body of evidence that says, “Actually, there are other risks”, and that looking at and assessing risk in relation to the end product misses disruption within the genome, and the potential health and safety aspects of that.
Disruption in the genome is at the heart of genome editing technologies, because you are going right into the cell—into the organism. I have to say, I think it is unfortunate that this Committee has not taken oral evidence from the number of scientists who work in medical practice and agriculture who have looked at the evidence of the risks of this damage within the genome and what that means, and can talk about it much better than me.
In our view, the extent of the damage and disruption within the genome is a contested area. The question then is: what does that mean for the composition of the final product, and what level of risk assessment is appropriate? That is another critical issue in this scientific debate. A number of witnesses on Tuesday referred to proportionate regulation and proportionate risk assessment. We absolutely agree with that, but it is a question of how you discuss proportionate risk assessment. Other regulatory authorities work on a system of tiered risk assessment and risk safety analysis, with different tiers for different levels of the application of this technology. We think that really should be looked at. To come back to your question, the evidence of safety and the evidence of risk is in our view entirely dependent on that tiered risk assessment.
Q
Lawrence Woodward: We are not opposed to the overall application of biotechnologies. Some aspects of genetic engineering technologies are very interesting, and there is certainly some amazing science happening. We are not opposed per se; it is about the context, the framework, the risk assessment and the wider social utility and environmental impact assessments.
I should just say that it was probably out of scope to call people who are much more based in the world of the human genome, but of course we know what advances have been made there using this technology.
Q
Dr Edenborough: The Bill itself does not purport to alter the intellectual property regime at all, so therefore this Bill will not have any effect on the underlying mechanisms whereby you can obtain protection—be that, for example, plant breeders’ rights or a patent. Therefore, it will still be open to small and medium-sized enterprises to secure rights as they would have done. To that extent, this has no effect.
Q
Professor Hartley: The Bill enables science to develop in this area, but it does not enable us to direct the science and technology towards doing any good. That would require a different form of governance. We know that gene editing and genetic modification are used in similar ways because we have not seen them separated out in any great detail yet globally. There have been some successes, but there have also been some failures—I would point to the GM cotton in Africa, particularly in Burkina Faso, where it failed to deliver the benefits and, in fact, had quite a negative impact. The question is whether the Bill can provide any public good; the answer is that it would make no difference to the public good. It may allow gene editing to develop, but whether or not it serves the public good would require a different level of governance.
Q
Professor Hartley: We could leave it to philanthropists, but the process of governance within the philanthropy organisations is quite closed and run by very few people, often within the United States of America. Social scientists working in this space have shown that we need more people from the area where the problem is based to be engaged and involved in the development of the technology. You would need stakeholders, farmers, conservationists and so on to be involved in the development of the technology early on.
Q
Professor Hartley: Indeed. That can happen as early as the funding agencies that fund the research all the way through the development and design process.
Q
Professor Hartley: One of the challenges the Bill faces is that it does not address the results from the consultation that DEFRA held. Some important issues came up through that consultation—around transparency, traceability, labelling and engagement—that do not appear to be addressed at the moment. I also think the focus of the Bill on the consultation has been around agriculture, and yet applications in conservation and environmental management are also possible in the Bill. There are a range of stakeholders in those areas who have not been sufficiently engaged, I believe, in the development of the Bill.
Welcome to the Committee. For the next session, we have until 3.50 pm. Would you please briefly introduce yourself by telling us your name and position?
Ed Barker: I am Ed Barker, head of policy at the Agricultural Industries Confederation. We represent agri-supply businesses in the UK, including animal feed companies, manufacturers, seed suppliers and distributors, fertiliser suppliers, arable marketing companies, grain traders and crop protection distributors. We also run a number of assurance schemes covering those individual commodities and products.
Q
We have focused a great deal on food in our two days of conversations with witnesses. Can you expand a little more on what benefits there might be within the feed sector?
Ed Barker: We can certainly see potential benefits in the feed sector. There are a number of challenges across UK livestock sectors at the moment, and feed is a considerable way in which we can address issues such as reducing our reliance on imports, particularly of high-protein products such as soya from South America, and divert that to UK—in this case, England—sources. We also see huge benefits by way of having a greater number of crops available to UK growers. By doing that, we also provide a better feed market, particularly in crops such as oilseed rape, peas and beans, which often either provide direct feed or are made into feed by processing.
We can also see other potential benefits in feed additives and feed products as a way of reducing emissions. It was interesting that the food strategy announced a couple of weeks ago referred to this issue, and innovation technology is certainly a way in which we can look to address that. Looking far ahead, there is some really pioneering work looking at the digestibility of certain grasses that can be fed to monogastric sectors, such as pigs and poultry. There are some very interesting areas where we could really look to change a lot of the challenges that we know the supply chain has with regard to animal feed.
Q
Ed Barker: To take those one by one, certainly the opportunities are there, and the uptake opportunities would certainly come in. A question we often get asked is: “How soon can the benefits be realised?” That is very difficult, particularly in combinable crops, which obviously have a much longer cycle of research and turnaround to be able to realise the benefits. From our point of view, however, the Bill’s benefit is that it provides long-term flexibility—five, 15 or 20 years—for growers, farmers and agri-supply businesses around the UK. We know the world is moving on quite quickly. We have heard about Canada and Japan, and even the EU is not static on this issue. There is a huge amount of interest. If nothing else, we are preparing ourselves for the inevitable demands on innovation in the future.
For take-up from a farming point of view, one area that we really want to focus on, particularly in the trade, is what we call the fungibility of goods. If you take cereals, for example, a real benefit to growers at the moment is that there are multiple markets available to them. For feed wheat, there are markets in the animal feed sector. It can also be exported or go to biofuel sectors. Having that flexibility is a real benefit to a lot of growers, and it provides a lot of resilience in businesses.
A short-term challenge that we could see is that if a product were considered to be gene edited, of course, at the moment in the EU that would be considered GM. As a result, we would have to go through quite an extensive approvals process to export that product to the European Union. That is a big part of the fungibility and flexibility of the product, so in the short term, we are only really likely to see benefits if it goes into the UK or England as a market.
However, a potential opportunity would be to have within the Bill a parallel process in place whereby authorisations were made for approval in the European Union when a product is approved for release by the Secretary of State. That would make a big difference, because inevitably, no farmer or grower is going to grow a crop that has a very limited market available to it. The next witness will probably be able to talk about that in a lot more detail. That is a real difficulty, and in the trade, if you are trying to buy and sell these products and you have a very limited outlet market in place, you might actually find that the product has less of a market the more of it you have, and there may be a deficit. To take the example of assurance in the supply chain at the moment, if you have unassured wheat, it usually trades at a discount because the market available to it is less. I do not want that to stop the Bill from progressing, but it is a short-term to medium-term challenge that we have to recognise, given the EU’s importance. In the past year, for example, we have exported about 1 million tonnes of cereal grains to the European Union, including the Republic of Ireland, so that flexibility is important.
Labelling has been mentioned. I think overall, labelling would be extremely difficult for the trade, because you need to label something right the way from start to finish. Let us take milling wheat as an example. You have to be able to define whatever the label is—gene edited or non-gene edited, GM or organic—and demonstrate that across the whole supply chain, and the compliance is quite strong. To do that, you have to segregate, and segregating throughout the supply chain is extremely challenging, very expensive and very difficult to do. The reason why it happens, for example, in the organic sector is that there is a market for it; the organic control bodies ensure that, but there is a market for it to ensure the additional costs of segregation are put in place.
With precision breeding—which, according to the Bill documents, can be bred by conventional means; it is just that it is quicker—the market would not see any great benefit from that. There has to be a pull factor for labelling, which would usually come as a result of added value, a health claim or a fortification, and the FSA and other bodies would already be asking for that evidence. If you are providing a claim on allergens or fortification with vitamins, the burden of compliance and providing that information will probably be much higher than anything that you do on precision breeding or gene editing labelling. The traders in the agri-supply business and throughout the supply chain would see no benefits whatsoever from labelling. In the trade, it would probably kill off a lot of the provisions in the Bill completely, because it just would not be economically viable to do.
Q
Ed Barker: It would depend on the approval processes set out by the FSA, in this case. Breeders, companies, developers and the market would look at the process to go through for receiving authorisation as laid out in the Bill, whatever it might be for—an environmental benefit, lower inputs at the crop end, or a fortification or a food benefit at the other end—and if they feel that it is too laborious and too challenging, and too much evidence or time is required to do it, it is very unlikely that those technologies will move ahead, so the implementation of this is really important.
We see it, for example, in the UK for certain minor use crops such as linseed, where a number of businesses have had to seek authorisation for individual farm protection products because they are essential for that particular crop. The problem is that it is often unviable to make that authorisation because the crop in the UK is such a small size. That does not necessarily mean it will always be unviable—far from it. It depends entirely on the role of the FSA and the approval processes that are set in place.
It could well be that UK markets are available for precision bred goods, whatever they might be. We have mentioned animal feed, but other food items and even non-food and feed products could have a genuine market uptake. For example, a retailer may well want to seek to remove or lessen the amount of soy in monogastric diets, and may look to work with a plant breeder to develop a crop that has a high protein source. That could be carried right the way through to the retailer’s end products. In those situations, I can see it as viable in the short term, but it depends on the type of products we are looking at and the type of markets we have in the UK.
Thank you very much. We will move on to questions, starting with the Minister.
Q
Paul Temple: That is quite a lot.
It is, but you can answer as much or as little as you like.
Paul Temple: I took part in the field-scale evaluation trials because I was sceptical, but I have always had an interest in science. I participated because it would expose me to field-scale working with these crops. I then realised my naivety about the amount of science and genetics behind breeding. I certainly learned, to my horror, how the quality of the scientists tended to be lumped against those protesting with a subjective view rather than an objective view. I learned then about appreciating the science behind genetics, but I would not have done unless I had participated.
A lot of farmers in the UK will not have been exposed to what I have, so they will not appreciate it. With farmers, you tend to find that if something works and is of benefit, they are pretty quick adopters. They tend to adopt it most when they have seen other farmers adopt it. I adopted conservation agricultural practice because I had seen that it did work. I am hoping that trials will happen as part of this to allow farmers to see it first hand in their own geographic region. Then they will make their own decisions. Usually if something works, they are pretty quick at picking something up.
Across the world, I think my frustration, especially being involved in Europe, is with Spanish farmers. I have seen GM maize grown in Spain, and they grow it because they had a problem. GM solved the problem, and they use a lot less water to produce more crop. It just made pure commercial sense, and that primarily is what drives it. It is usually a matter of making commercial sense. GM delivers benefits in terms of reduced inputs. It usually comes with significant environmental benefit, because you are reducing your pesticides load, and that tends to get mixed up. Again, from a UK perspective, because I have seen what happens in south and north America, I understand the scale of adoption and what it has delivered into the marketplace in meeting China’s demand for maize and soya, which is unusual for most farmers.
On the co-existence element, we obviously had to closely monitor it when we were growing these crops. We did not change any practices, found no problems looking after the crops and found no problems subsequently with volunteers that might be left over. We continued with trials on those, and that was not an issue. Co-existence really is not much of a problem. In any country I have been to, that is not the issue. It is usually the access to it that is a limitation. It has always fascinated me that a lot of the small farmers in Africa and Asia are given access to technology in a way that you cannot appreciate, which delivers benefit to them. Have I missed anything out?
No, that was perfect. It was an interesting contrast between the field—literally—and to how this can help on a global basis, rather than from a more academic standpoint. It is an interesting juxtaposition to what we heard earlier. Thank you very much.
Q
Paul Temple: Obviously, I am not an expert in these particular areas, but I do not think we have anything to hide, so public registers—registers of seed varieties and what we are growing—are really important. What you put in the public domain, to my mind, has to be measured by what benefit or what risk there actually is. I suppose my frustration with the field scale evaluation trials was that, by making everything public, it just highlighted those who wanted to protest, rather than actually look at the science. So I think is it really important that whatever element goes into this Bill is done from a science perspective and a risk-based perspective. I do not have any problem with being open as to what is happening on my farm. I think it is really important, but there just has to be some kind of sensible balance, so that it does not drag things down to where you cannot do anything.
Excellent. Would you introduce yourself for the record, please?
Ross Houston: I am Ross Houston, I am currently the director of innovation at Benchmark Genetics, which is an agriculture breeding company supplying genetically improved Atlantic salmon, whiteleg shrimp and Nile tilapia for various global markets. I am fairly recent to the role; in my previous role I spent 18 years as a researcher at the Roslin Institute as part of the University of Edinburgh.
Q
Ross Houston: What we are currently doing is running family-based breeding programmes for genetic improvement of several traits in Atlantic salmon, whiteleg shrimp and Nile tilapia. Those traits, of course, include growth, but we are also focused on improving the resistance of the animals to infectious diseases. Some examples in salmon are sea lice and some viral diseases. That is not precision breeding as I understand it but family-based selection using genomic tools. We are undertaking research and development in the use of CRISPR.
I am talking to you from Norway because I was attending a project meeting where there are two large consortia—one Norwegian funded, by the Norwegian seafood agency, and one funded by the BBSRC, primarily geared towards using CRISPR as a tool to achieve substantial and possibly complete genetic resistance to sea lice in Atlantic salmon. The reason we are excited by those projects is that sea lice are currently one of the most pressing environmental, cost and animal welfare concerns for the industry. In particular, I would say that some of the treatment measures that we are using and, indeed, are obliged to use, have several downsides that I think we could potentially avoid if we were to develop resistant salmon that did not require those treatments. In so doing, we are not only improving the animal welfare but reducing the impact on the environment and improving the economics of the industry.
Q
Ross Houston: The Bill is a welcome initiative. It has been really useful to have this debate and discussion, because we see that CRISPR or similar technologies can help us achieve traits that are of benefit to animal welfare and the environment faster than we could do with conventional breeding alone—substantially faster in some cases. That is why we are investing in it. That is why the research councils, Government and industry in general are investing in this technology.
This technology is developing fast, I agree. It is exciting to scientists involved in it. We are narrowly focused on using CRISPR to introduce changes that could potentially have occurred naturally, so I think that is a welcome part of the Bill, that we are mentioning that those changes could occur naturally, via natural mutation. We are adding to the genetic variation that we have in our toolbox to select for. The way I see it is that CRISPR would ideally be a tool in the toolbox alongside the technologies that we use currently to develop improved strains of salmon and other species for production.
I think that a register of precision breeding would be a reasonable measure. I would be worried about going too far in trying to identify whether any particular product contained any particular edit, for example. That might be disproportionately difficult and complex, and to my mind without any real scientific basis. I do see that, if you were changing the genetic makeup of a plant or animal to have some potentially different human health benefit, such as removing allergens or something like that, there might be a rationale for labelling that particular edit. In this case, however, I think that the register is reasonable, but that the practicalities of tracing through particular edits would make that very unattractive to implement in practice, because of the logistical impracticality of doing so.
Q
Ross Houston: Obviously, there are measures to try to stop escapees, but they happen from salmon farms. I think that CRISPR precision breeding technologies are a very promising route, and indeed the subject of much R&D, to ensure that the production animals are sterilised so there would not be any genetic introgression with wild strains. The way we are thinking about it, at least, is that we would be looking to farm sterile Atlantic salmon in the future. That is a desirable thing to do anyway, but in particular if we were to introduce gene editing in the future.
The other part to it would be, I suppose, the impact of issues such as sea lice, which I mentioned before, which could also impact on wild salmon. But, there again, that is within our toolbox, and the R&D is heading in this direction. That is what we would want to use the technology for: to try to tackle these problems in a sustainable, environmentally friendly and animal welfare-friendly way. So I see that these technologies have significant promise for reducing any potential impacts on wild Atlantic salmon.
Q
Ross Houston: I see what you mean. Of course CRISPR, the technique we are focusing on, is making a double-stranded cut to the genome and allowing the cells’ natural repair mechanisms to repair the cut and either introduce a small deletion or a small change, or possibly insert a synthetic template of DNA, which would essentially be changing the sequence in a slightly more precise way. There are a couple of parts to that.
In terms of the potential for the CRISPR molecule to make cuts elsewhere in the genome—called off-target effects—we would have to be doing some fairly rigorous DNA sequencing of our animals to ensure that we are not detecting any of those off-target effects. My opinion is that we are now getting very good data from research experiments showing that off-target effects are very rare, and as we learn more about the genomes of our species we are able to design the guide RNAs to take to a specific part of the region that is unique and precise. I see that as a very small risk, but also one that it is important to address.
Q
Ross Houston: Yes. I moved job recently; I was working for a number of years at the Roslin Institute doing academic research together with industry. The Scottish Government centre, the Sustainable Aquaculture Innovation Centre, is funding projects using precision breeding technologies as a research tool with the goal of—
Q
A very quick response.
Ross Houston: Yes, of course. As I mentioned earlier, the Scottish and UK science base is really at the forefront of some of these technologies, moving through from genetics, traditional breeding, family-based selection, genomics and now gene editing. That is a real plus point for attracting researchers. If we were to stop unnecessarily, both in research and potential applications, then it is a fair assumption that we would lose talent to elsewhere, and I think we would also lose business to elsewhere.
Thank you. We will finish this session at 5.10 pm. I will move straight to questions, but I ask our witnesses not to say if they agree with somebody; that just takes time. If there is a different point of view, we are interested in that.
Q
Professor Caccamo: I think there are two components to the question. First, the benefit is clearly in incentivising investment in human capital. There is a lot of expertise in the UK—we are global leaders. Investment has come from the public sector. Taxpayer money has been put in place to develop skills, and seeing those skills put into practice would be fantastic. I see that as the biggest benefit. I will leave that there because my colleagues here will probably bring in other points.
On concerns and improving the Bill, I think the Bill is very balanced in terms of the definitions. There is a space left open for how much downstream regulation might be required, which I think is probably unnecessary and not proportional to what we might want to achieve with the Bill. The principle behind the Bill is that we would like to consider genome edited crops in the same way as any other crop that has been bred using traditional technologies. With that in mind, we should look into anything that comes downstream in terms of how we use outputs from these technologies in a proportional way. There is probably space there to be less specific and include so much detail, which could potentially be a deterrent for industry if it seen as adding unnecessary steps downstream. That is my main concern.
Q
Nigel Moore: Transparency is really important. As plant breeders, we do not have anything to hide. One thing that is often overlooked is that within the current regulatory regime around plant rights and seeds, there is already inherently a lot of transparency and traceability in terms of registering new varieties on national catalogues in the public domain, which will have had an identity check and at least two years of performance checking through DUS and VCU, which test for distinctiveness, uniformity and stability, and value for cultivation. The seeds of those varieties are then sold as certified seed with clear labels, with the variety name, batches, qualities, plant health status and operator identity all held within the seed certification regulation. We believe that allows a lot of traceability, so the transparency that is envisaged in the Bill of adding breeding method and genome edited varieties to the national register enables the market to segregate as it wishes.
Varieties will be suitable for markets or not. They can very easily select which varieties to enable within a standard, such as an organic standard. The one with the organic standard can say, “No, I don’t want to use variety A, B or C because it is genome edited”, and that is on the public register as envisaged in part 2 of the Bill.
Q
Professor Martin: Really, getting something that might translate into a product. I am a fundamental research scientist. I want to do things that have social utility, and I believe very strongly in improving the number of plants in our diet because that benefits health. I started off trying to do this by genetic modification and we made purple tomatoes with their GMOs. Fourteen years later, I am about to get them approved for commercialisation in the USA. It has taken me 14 years to get to that point. For the pro-vitamin D tomatoes, because they qualify as having no foreign DNA in them, that means I can even start within 20 days of notifying DEFRA under the new legislation. I can have a field trial of them. I could not possibly have a field trial of the purple tomatoes, so for me, it is the realisation that this could actually be something we could give to people that would be better for them. It might actually happen.
Q
Professor Harwood: I will just say that I am here in a personal capacity, not as a representative of the committee. Obviously, food safety is extremely important, and a lot of the things that the technology can do—we have heard many examples—are almost identical to things that could have been done using other methods, for example, through mutation breeding.
However, there are some things that the technology could do, and Cathie’s tomato is one example, and there are others, of where a change would be made. It would still be just a tiny change in the DNA—something that could have happened naturally, but has not happened naturally so far—but it is making a change that might cause concern for certain people in the population.
Another example might be something like a low-gluten wheat. You can imagine that this would be something that would need a bit of extra scrutiny. There might be a food safety issue there, so it would need to be looked at. It is very much looking at things on a case-by-case basis. You would need to pick out those things that would need that extra level of scrutiny and risk assessment from those that probably need very light-touch regulation.
Q
First, you will all recall the public confidence issues from 20 or 30 years ago, and that is one of the challenges now. I would like to hear whether you think the Bill has enough in it to reassure the public around some of those issues. Secondly, and in some ways related to that, most of you are plant focused, but this Bill obviously introduces animals, which is a very different set of issues and is, in some ways, perhaps more challenging. Do you think they should have been separated out? Thirdly, what do you think the public register will be used for and what benefit does it bring?
Finally, specifically for Cathie and Wendy, I had a constituent contact me, who has an issue around vitamin D being added to tomatoes. How will that constituent know whether these tomatoes have been modified in that way in future? It touches on Professor Harwood’s final point, and goes back to my initial point, on the question of labelling and reassurance. Where should that balance be struck?
Professor Harwood: Shall I take the last question first? We have talked a lot about labelling. If there was something like a high vitamin D tomato, there would be a nutritional difference, which I imagine would be picked up on labelling. That would make sense.
Professor Martin: You would probably want to advertise it.
Professor Harwood: You probably would, yes. Where there is something that might be appropriate for certain members of public and not others, clearly you would want some sort of labelling.